Innovating Works

Janssen Vaccines (f.k.a. Crucell Holland...

Desconocido
VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado
IDERHA: Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance JANSSEN VACCINES PREVENTION BV participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced...
2023-05-10 - 2028-03-31 | Financiado
iAds: Intelligent design of adenovirus vectors (iAds) JANSSEN VACCINES PREVENTION BV participó en un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDEROPEN-01 Advanced therapies, and in particular gene therapies, hold great potential for treating diseases for which few options exist. Efficient gene...
2022-12-20 - 2027-04-30 | Financiado
PrIMAVeRa: Predicting the Impact of Monoclonal Antibodies Vaccines on Antimicrobial Resistance JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage Antibiotic resistance (AMR), a major threat to human health, is increasing in all bacteria through antibiotic-induced selection, cross-speci...
2021-11-09 - 2026-10-31 | Financiado
INITIATE: INnate ImmunomeTabolIsm as Antiviral TargEt JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-MSCA-ITN-2018 Viral outbreaks and epidemics continue to impose high morbidity and mortality burdens in mankind and animals, emphasizing the urgent need fo...
2019-05-21 - 2023-04-30 | Financiado
VITAL: Vaccines and Infectious Diseases in the Ageing PopuLation JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VI...
2018-12-10 - 2024-12-31 | Financiado
EBOVAC3: Bringing a prophylactic Ebola vaccine to licensure JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-JTI-IMI2-2015-08-single-stage The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the...
2018-06-15 - 2024-09-30 | Financiado
OptiMalVax: Optimizing a deployable high efficacy malaria vaccine JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-SC1-2016-2017 A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vacc...
2016-12-09 - 2022-12-31 | Financiado
EDGE: Training network providing cutting EDGE knowlEDGE on Herpes Virology and Immunology JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-MSCA-ITN-2015 Herpesviruses are widely spread, and cause life-long infections. Most individuals carry multiple herpesviruses, which can cause severe disea...
2016-04-05 - 2020-10-31 | Financiado
EHVA: European HIV Vaccine Alliance EHVA a EU platform for the discovery and evaluation of novel prophy... JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-PHC-2014-2015 Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. T...
2015-12-17 - 2023-12-31 | Financiado
EBOVAC2: Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime Boost Regimen Phase II So... JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-JTI-IMI2-2014-02-single-stage The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBO...
2015-03-06 - 2021-05-31 | Financiado
EBOMAN: Manufacturing and Development for Rapid Access Ebola Vaccine EBOMAN Sofia ref. 115850 JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-JTI-IMI2-2014-02-single-stage This topic response (Topic 2: Manufacturing Capability) forms part of an integrated proposal to address the urgent unmet needs of accelerati...
2015-03-06 - 2017-11-30 | Financiado
EBOVAC1: Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime Boost Regimen Sofia ref.... JANSSEN VACCINES PREVENTION BV participó en un H2020: H2020-JTI-IMI2-2014-02-single-stage The overall aim of the EBOVAC programme is to assess the safety and efficacy of a novel prime boost prophylactic vaccine regimen against Ebo...
2015-03-05 - 2021-11-30 | Financiado
FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... JANSSEN VACCINES PREVENTION BV participó en un FP6: Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
2015-03-01 - 2020-02-29 | Financiado
ADVANCE: Accelerated Development of Vaccine benefit-risk Collaboration in Europe JANSSEN VACCINES PREVENTION BV participó en un FP6: Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
2013-10-01 - 2019-03-31 | Financiado
AD-VEC: Adenovirus Vector Technology Next Generation Systems for Medical Therapy JANSSEN VACCINES PREVENTION BV participó en un FP7: We propose a programme (AD-VEC) involving two industrial and three academic partners with the aim to identify new adenoviral vectors as vehi...
Financiado
ADVANCE: ADenoViruses as novel clinical treatments JANSSEN VACCINES PREVENTION BV participó en un FP7: ADVance is designed to integrate 8 leading academic centres and 4 private companies under a single umbrella to create an opportunity to tra...
Financiado
FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... JANSSEN VACCINES PREVENTION BV participó en un FP7: Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
Financiado
ADVANCE: Accelerated Development of Vaccine benefit risk Collaboration in Europe JANSSEN VACCINES PREVENTION BV participó en un FP7: Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.